Host William Lou recaps the Toronto Raptors' 116-112 loss to the Detroit Pistons.
Host William Lou recaps the Toronto Raptors' 116-112 loss to the Detroit Pistons.
Coverage of Prince Philip's death sparked 109,741 complaints.
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Manus Bio, Inc. (Manus Bio), a leading US manufacturer of sustainable natural ingredients, announced today the launch of NutraSweet Natural™, a plant-based sweetener with zero calories and 100% pure tasting sweetness to enjoy in daily life. Manus Bio is paving the way for next-generation calorie reduction with a unique green technology for sourcing nature’s sweetest ingredients while minimizing its environmental footprint. Despite their initial appeal, traditional alternative sweeteners have typically been associated with an unpalatable aftertaste, making them an imperfect alternative to sugar. With this hurdle in mind, NutraSweet Natural™ was created by isolating only the sweetest, purest parts of the stevia leaf and incorporating them into a proprietary blend to create the taste of sugar without the calories. The result is a revolutionary natural sweetener with a clean “just-like-sugar” taste with none of the guilt or aftertaste of traditional alternative sweeteners. “Consumers today are prioritizing health, wellness, and sustainability and are increasingly demanding better, tastier, and healthier options for the foods and ingredients that they consume. According to the Centers for Disease Control and Prevention, a staggering 49% of all Americans have tried to lose weight in the past year. We are proud to be able to offer a unique next-generation zero-calorie sweetener that allows us to indulge in sweetness while maintaining lifestyle goals,” said Brendan Naulty, President of Sweeteners & Natural Ingredients at Manus Bio. Heather Barbarino, VP of Marketing and Communications, added, “NutraSweet™ is an American brand that has delivered sweetness to consumers for decades. We are thrilled to re-introduce the brand with the launch of NutraSweet Natural™. It revolutionizes sweetness to offer consumers a healthy alternative with a natural great taste. As a critical part of NutraSweet Natural™, its unprecedented taste profile was designed with deep respect, empathy, and appreciation for nature. Simply put, we’re Keeping Nature Natural, NutraSweet Natural™ is both good for you and good for the planet.” Be among the first to taste NutraSweet Natural™ sweetener with a 70-count box of sachets available for purchase at www.nutrasweetnatural.com. About Manus Bio:Manus Bio leverages rapid advances in biology to produce complex natural ingredients used in our daily lives as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural products. Using its proprietary fermentation technology, Manus Bio recreates advanced natural processes for next-generation biomanufacturing and provides sustainable and cost-effective sources of ingredients for health, wellness, and nutrition. To learn more, visit www.manusbio.com. CONTACT: Contact: Heather Barbarino, VP of Marketing and Communications E-mail: email@example.com
In March, “Novaturas” Group resumed flights from Lithuania, Latvia and Estonia to Tenerife and Egypt. From Vilnius airport plains took off to United Arab Emirates and Maldives. During March, the Company served 6.4 thousand customers – 18% more than in the corresponding period last year. If compared to 2019, the number of customers served in March 2021 reached half the number of customers served in 2019. In total, during January - March, the Company served 8.9 thousand customers - 71% less than last year and 78% less than in 2019. Group revenue in March amounted to EUR 4.1 million and was 6% lower than the same time last year and 59% lower than in 2019. Cumulative January - March turnover reached EUR 5.5 million and was 76% and 81% lower than the corresponding time last year and in 2019. "March 2021 has been noted by two positive aspects - we have finished refunding our travelers for the trips that have been cancelled due to the pandemic, and we have served 18% more customers than during same month last year. If compared revenues we have generated this March and in March 2019, we are only 6% behind. These achieved results might look modest if compared with operational and financial results generated in 2019, but in today's context it is a big step forward towards more sustainable planning”, says Audronė Keinytė, Head of “Novaturas” Group. In April, the Company have resumed flights from all the Baltics to the most popular summer holiday destination - Turkey. The first plane took off from Vilnius on the 1st of April – the earliest of all the Baltics. Flights from Tallinn have started on the 3d of April, and plains from Riga will take off on the 21st of April. Winter holiday programs to Egyptian resorts and Tenerife are also continued in April. Flights to other popular summer destination Greece is planned to start in May if the epidemiological situation is in favor. About “Novaturas” Group AB “Novaturas” Group is the largest tour operator in the Baltic States, offering summer and winter package holidays in more than 30 destinations worldwide and more than 100 sightseeing routes. In 2019, the group served more than 293 thousand customers. CFOTomas Staškūnas firstname.lastname@example.org, +370 687 10426
Proxima CRO, based out of the Texas Medical Center, announced today it has experienced tremendous growth in clients, clinical studies, and new hires.
The "Global Cranes Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
PartsSource President & CEO Philip Settimi, MSE, M.D., has been named to The Healthcare Technology Report’s 2021 Top 50 Healthcare Technology CEOs
“It was the most challenging year of my professional career,” the USC coach said.
Kudela cupped his hand when he made the remark to Finnish player Kamara at the end of a Europa League last 16 game at Ibrox on 18 March.
The "Global Healthcare Discount Plan Market (2020-2025) by Service, Deployment Model, End user, Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
Nearly 750,000 vehicles built by Chevrolet, GMC, and Cadillac are the subject of a National Highway Traffic Safety Administration (NHTSA) investigation due to non-deploying driver-side airbags. While the investigation is ongoing, the agency believes the issue is likely due to rust particles that form on the inflator's connection terminal interface. The list of nameplates included in the investigation includes Chevrolet's Silverado, Tahoe, and Suburban, GMC's Sierra, Yukon, and Yukon XL, plus Cadillac's Escalade, Escalade ESV, CT4, CT5, and XT4.
Apple has launched a $200 million Restore Fund to capture CO2 by reviving forests.
And the way the kids "relate" is just so damn funny.
Netflix has given a 10-episode straight-to-series order to sci-fi drama The Imperfects, starring Italia Ricci (Designated Survivor, Chasing Life), from The Order‘s Dennis Heaton, Shelley Eriksen and Nomadic Pictures. Written by Heaton and Eriksen, in The Imperfects, after an experimental gene therapy turns them into monsters, three twenty-somethings band together to hunt down the scientist […]
Austin, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Lightspeed Systems®, the leading K-12 online safety and effectiveness solutions provider, announces the launch of Lightspeed Alert™, a threat detection solution for self-harm, bullying, and school violence, helping to provide schools and districts with early warning detection to prevent incidents and promote student safety. Statistics regarding student mental and physical safety are startling. A recent survey found 93% of parents are concerned about their child’s mental health due to extended campus closures and isolation, and another study from the U.S. Secret Service found 75% of school shooters demonstrated concerning online activity before the incident took place. With these concerns, it’s critical for schools and districts to have the type of early warning threat detection that Lightspeed Alert can provide. Lightspeed Alert leverages smart AI to actively scan and alert on concerning student behavior anywhere students engage online. Real-time alerts and safety dashboards equip district and school staff with the visibility and tools to respond to threats and manage cases. For an extra layer of protection, Lightspeed Alert provides 24/7/365 human review by highly trained safety specialists who conduct a threat assessment of flagged behavior and escalate imminent threats via a live phone call to school district personnel or law enforcement. “With student mental health at a new low, and the ongoing societal challenge of mass shootings, we need to move the conversation from preparation and response to violent incidents to mitigation and prevention of those incidents,” shares Eileen Shihadeh, CMO at Lightspeed Systems. “We developed Lightspeed Alert to do just that, and to further our mission of keeping kids safe.” About Lightspeed Systems With over 20 years providing technology to meet the needs of schools, Lightspeed Systems is the market leader in online student safety and effectiveness. The purpose-built Lightspeed ecosystem of cloud-based solutions – tailored to meet today’s evolving challenges – provides schools worldwide with reliable filtering, analytics, and device management tools for school leaders and educators. Lightspeed Systems is a proven partner for schools, serving over 30 million students in 38 countries and 30,000 schools globally. To learn more, visit www.lightspeedsystems.com. CONTACT: Ida Yenney KCPR for Lightspeed Systems email@example.com
Forecasts by Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity, Other Disease Causes), by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cencicriviroc, Other Drug Type), by Sales Channel (Hospital Pharmacy, Online Suppliers, Retail Pharmacy, Other Sales Channel) AND Regional and Leading National Market Analysis PLUS Analysis of Leading NAFLD & NASH Companies AND COVID-19 Recovery ScenariosNew York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031" - https://www.reportlinker.com/p06061840/?utm_source=GNW What is holding you back in the Non-alcoholic Fatty Liver Disease & NASH Business?NASH is presently diagnosed by methods such as blood test, imaging or a liver biopsy. These tests are time consuming and have less certainty as they are generic tests. Imaging techniques like CT, MRI and Ultrasound scans were inaccurate to diagnose NASH. These tests are not just incorrect for NASH diagnosis but also cost a lot. This absence of conclusive diagnostic methods in order to detect NASH, is the major challenge to the NASH market.Our 330+ page report provides 275 tables, 191 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing non-alcoholic fatty liver disease & NASH market. Buy our report to see how to exploit these opportunities in the global market.Forecasts to 2031 and other analyses reveal the commercial prospects. In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.. You find original analyses, with business outlooks and developments.. Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments.Discover sales predictions for the global non-alcoholic fatty liver disease & NASH market and submarketsAlong with revenue prediction for the overall world market, there are 5 segmentations of the non-alcoholic fatty liver disease & NASH market, with forecasts for 5 Disease Cause, 5 Drug Types, 3 Types, 4 Sales Channel each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.Leading companies and the potential for market growthAs per the analysis, global non-alcoholic fatty liver disease & NASH market is estimated to be valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.What all Segments Are Covered in the Report?Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause (COVID-19 Impact Recovery Analysis Covered). Hypertension. Heart Disease. High Blood Lipid. Type 2 Diabetes. Obesity. Other Disease CausesGlobal Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type (COVID-19 Impact Recovery Analysis Covered). Vitamin E & Pioglitazone. Ocaliva. Elafibranor. Selonsertib. Cencicriviroc. Other Drug TypeGlobal Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel (COVID-19 Impact Recovery Analysis Covered). Hospital Pharmacy. Online Suppliers. Retail Pharmacy. Other Sales ChannelGlobal Non-alcoholic Fatty Liver Disease & NASH Market by Region (COVID-19 Impact Recovery Analysis Covered). North America. Europe. Asia-Pacific. Latin America. Middle East. AfricaNeed industry data? Please contact us today.Which Key Players Are Leading the Global Market and how much Share do they Hold?The global market for non-alcoholic fatty liver disease & NASH is ascending and has made significant gains in NASH treatments. The players in the non-alcoholic fatty liver disease & NASH market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:. Mergers and acquisitions.. Product launches.. Collaborations and partnerships.Product approval is a major milestone facing all key competitors in the non-alcoholic fatty liver disease & NASH market. Several strategies were implemented by key market players between 2015 and Jan 2021. There are over 100 pharma companies involved in different aspects of NASH therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.How the Non-alcoholic Fatty Liver Disease & NASH Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated. What is the current size of the overall global non-alcoholic fatty liver disease & NASH market? How much will this market be worth from 2021 to 2031?. How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?. Who are the leading companies and what are their activities, results, developments and prospects?. What are some of the most prominent human non-alcoholic fatty liver disease & NASH currently in development?. What are the main trends that will affect the world non-alcoholic fatty liver disease & NASH market between 2021 and 2031?. What are the main strengths, weaknesses, opportunities and threats for the market?. What are the social, technological, economic and political influences that will shape that industry over the next ten years?. How will the global non-alcoholic fatty liver disease & NASH market evolve over the forecasted period, 2021 to 2031?. Which NASH drugs and therapies can succeed and what revenues could they generate to 2031?. What will be the main commercial drivers for the NASH market from 2021 to 2031?. How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?. How will that industry evolve between 2021 and 2031, especially in R&D?Top 20 Leading Players Profiled in the Report. Pfizer Inc. (Pfizer). Roche Holding AG (Roche). Takeda Pharmaceutical Company Limited. Intercept Pharmaceuticals, Inc.. AstraZeneca PLC. Novartis AG. Merck & Co., Inc.. AbbVie Inc. (AbbVie). Gilead Sciences, Inc.. Genfit Biotechnology. Cardax, Inc.. Daewoong Co Ltd. Madrigal Pharmaceuticals, Inc.,. Mirum Pharmaceuticals, Inc.. GW Pharmaceuticals plc.Read the full report: https://www.reportlinker.com/p06061840/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Harvey Tyrrell suffered a fatal shock at the King Harold in Romford, east London.
The Scotland international joins fellow striker Billy Sharp in missing the rest of the campaign.
A lawyer for relatives of people killed in the 2014 downing of Malaysia Airlines Flight 17 over eastern Ukraine told a court hearing Thursday that 290 relatives and partners of the victims have filed compensation claims for “emotional distress" against the four suspects charged in the downing. Lawyer Arlette Schijns was speaking at a preliminary hearing in the long-running legal proceedings against three Russians and a Ukrainian charged with involvement in shooting down the Amsterdam-to-Kuala Lumpur flight on July 17, 2014. None of the suspects have appeared in court and the case is proceeding in their absence.
West Bengal on Wednesday recorded the highest single-day increase in COVID cases.
RF Capital Group Inc. (TSX: RCG) will release its first quarter 2021 financial results on Monday, May 10, 2021 at approximately 7:00 a.m. (EST).